

I GOT
MY COVID-19
VACCINE!



WE
CAN
DO
THIS



PHFPC COVID-19 Vaccine Debriefing

The information presented today is based on CDC's recent guidance and MAY change.

August 11, 2021

Saroj Rai, PhD, MPH

Senior Scientific Advisor | Office of Chief State Epidemiologist

COVID-19 Vaccine Update



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Moderna COVID-19 Vaccine

Booster Dose & Delta Variant

- **Six months durability data**
 - In final analysis of Phase 3 COVE study data, the Moderna COVID-19 Vaccine showed 93% efficacy, with the efficacy remaining durable through six months after administration of the second dose. COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose.
- **Addressing Variants of Concern**
 - In a Phase 2 study, vaccination with 50 µg of three different Moderna mRNA booster candidates induced robust antibody responses against the wildtype D614G COVID-19 strain and against important variants of concern including Gamma (P.1); Beta (B.1.351); and Delta (B.1.617.2).
 - The booster candidates included mRNA-1273, investigational mRNA-1273.351, and investigational mRNA-1273.211. Neutralizing antibody levels following the boost approached those observed after primary vaccination with two doses of 100 µg of mRNA-1273. These data have been submitted to a peer-reviewed journal for publication.



Pfizer COVID-19 Vaccine *Booster Dose & Delta Variant*

- July 8, 2021: the company announced that a booster dose given 6 months after the second dose elicited high neutralizing titers against the Beta variant.
 - The immune sera obtained after dose 2 of the primary two-dose series of the current vaccine had strong neutralization titers
 - The company has stated “...based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination. While protection against severe disease remained high across the full 6 months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected. Based on the totality of the data they have to date, Pfizer and BioNTech believe that a third dose may be beneficial to maintain the highest levels of protection.”
- Development of an updated version of the current vaccine specifically targeting the Delta variant is in progress. Clinical studies are anticipated to begin in August.
- The FDA has accepted Pfizer’s COVID-19 vaccine full licensure application with a response date by January 2022.



COVID-19 Vaccine Boosters

FDA & CDC

- At this point, the CDC is not recommending a booster dose for any of the three currently authorized COVID-19 vaccines in the U.S.
- The last two ACIP meetings have discussed booster doses in immunocompromised individuals
 - Booster doses
 - Are booster doses needed for all persons or only in specific populations?
 - What is the optimal timing of booster doses after primary series?
 - Can these be given as a 'mixed dose' or do they need to be matched to a primary series?
 - June 23, 2021: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/06-COVID-Oliver-508.pdf>
 - July 22, 2021: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf>



Pfizer COVID-19 Vaccine

Children Under 12 Years of Age

- The Phase 1/2/3 dose-escalation study in healthy children 6 months old to 11 years on a two-dose schedule (approximately 21 days apart) in three age groups:
 - Children ages 5 to 11 years
 - 2 to 5 years
 - And 6 months to 2 years
 - Children younger than 6 months of age may subsequently be evaluated, once an acceptable safety profile has been established.
- If safety and immunogenicity is confirmed, and pending authorization or approval from regulators, target to submit the vaccine for potential Emergency Use Authorization (EUA) to the FDA sometime in the Sept-Oct for children 5 to 11, and soon after for 6 months to 5.
- July 26, 2021: the FDA has requested to expand the number of participants in the clinical studies designed to detect rare adverse effects.

<https://www.pfizer.com/science/coronavirus/vaccine/additional-population-studies>



Texas Department of State
Health Services

Moderna COVID-19 Vaccine

- Filed a 'rolling submission' for a full approval to the FDA. The company stated completing their submission this month.
- No decision from the FDA on its application for expanding the current EUA to include ages 12 years and older.
- Ongoing pediatric studies in ages 6 months to 11 years of age.
 - No target filing dates with the FDA yet
 - The FDA asked to expand number of participants in the ongoing pediatric studies, similar to Pfizer pediatric studies.



COVID-19 Vaccine Texas Overall Summary




TEXAS
Health and Human
Services

Texas Department of State
Health Services

Percent People Vaccinated by Age Group by Vaccination Date

% 0-11 % 12-15 % 16-17 % 18-29 % 30-39 % 40-49 % 50-64 % 65-74 % 75+

1-dose includes one-dose Pfizer, Moderna, and J&J COVID-19 Vaccines




Data as of 8/9/21

	Population Estimates	People Vaccinated	Fully Vaccinated
Texas Total	28,995,881	15,346,852	12,889,294
% Total		53%	44%
>=12 y.o.	24,101,113	15,342,142	12,887,928
% >=12 y.o.		64%	53%
>=18 y.o.	21,596,071	14,246,545	12,134,908
% >=18 y.o.		66%	56%
>=65 y.o.	3,734,229	3,140,955	2,815,988
% >=65 y.o.		84%	75%


**People Vaccinated includes first doses of Moderna and Pfizer and single doses of Janssen.
Fully Vaccinated includes second doses of Moderna and Pfizer and single doses of Janssen.**

COVID Vaccine Order Requests

Week 31-36 (July 12 -August 16)



Doses administered by vaccination date 12+




7-Day Rolling Average Doses Administered by Dose Number

— First Doses 7-day Rolling Average



— Second Doses 7-day Rolling Average

First doses 7-day Rolling Average includes 1st doses of Moderna, Pfizer, and single doses of Janssen.
Second Doses 7-day Rolling Average includes 2nd doses of Moderna and Pfizer.



Data as of 8/9/21

COVID-19 Vaccine People Vaccinated 12+
FOR PLANNING PURPOSES ONLY
 Data provisional as of August 9, 2021





People vaccinated includes first doses of Pfizer/Moderna and single doses of Janssen. Completely vaccinated includes second doses of Pfizer/Moderna and single doses of Janssen.



TEXAS
 Health and Human Services

Texas Department of State Health Services

COVID-19 Vaccine Fully Vaccinated 12+
FOR PLANNING PURPOSES ONLY
 Data provisional as of August 9, 2021




People vaccinated includes first doses of Pfizer/Moderna and single doses of Janssen. Completely vaccinated includes second doses of Pfizer/Moderna and single doses of Janssen.



TEXAS
 Health and Human Services


Texas Department of State Health Services

TMD Teams Save Our Seniors
COVID-19 Vaccine First Doses Administered 65+
FOR PLANNING PURPOSES ONLY
 Information as of 8/9/2021



Texas Department of
 State Health Services

TMD Teams Save Our Seniors
COVID-19 Vaccine Fully Vaccinated 65+
FOR PLANNING PURPOSES ONLY
 Information as of 8/9/2021





Texas Department of
 State Health Services

COVID-19 Vaccine 12-17 People Vaccinated Out of 12-17 County Population

FOR PLANNING PURPOSES ONLY

Data provisional as of August 9, 2021





People vaccinated includes first doses of Pfizer/Moderna and single doses of Janssen. Completely vaccinated includes second doses of Pfizer/Moderna and single doses of Janssen.

COVID-19 Vaccine 12-17 Fully Vaccinated Out of 12-17 County Population

FOR PLANNING PURPOSES ONLY

Data provisional as of August 9, 2021



People vaccinated includes first doses of Pfizer/Moderna and single doses of Janssen. Completely vaccinated includes second doses of Pfizer/Moderna and single doses of Janssen.

DISCLAIMER

The information presented today is based on CDC's recent guidance and MAY change.

August 11, 2021